93% & 94% respectively for (S) MAM (Sm) 75 pg/ml has 98% sensitivity, 90% specificity & 97% accuracy for detec- tion of LV Dys either (S,D or both). BNP levels were significantly higher in patients with combined (S & D) Dys than those with only (S) Dys, the later group had sig- nificantly higher BNP levels than those with only (D) Dys, (1054.5±202.3 pg/ml vs. 500±39.9 pg/ml & 500±39.9 pg/ml vs. 215.3±100.9 pg/ml respectively & each was significantly higher than control group(12.3±5.7 pg/ml), p 50% reduction) and ULC (>20% reduction) criteria based on reduction of admission values upon discharge. Results: NT-proBNP values were 5454±6475 pg/ml on admission and 4482±1149 pg/ml at discharge (p=ns). ULCs were 24±17 on admission and 17±18 at discharge (p<0.01). There was a weak, albeit significant, correlation between changes from admission to discharge in NT-proBNP and ULC (r=0.337, p=0.03). The overall concordance between NT-proBNP and ULC criteria of responsiveness was 65%: see figure. cise test and blood sampling for IL-1, IL-6, TNF-a, its soluble receptors sTNFR1, sTNFR2, N-Terminal pro-ANP and pro-BNP (N-BNP). Results: At 12 months carvedilol pts showed an improvement in NYHA class (p<0.001) and LVEF (27.9£7.9vs 36.4±9.3%, p=0.001), while diastolic dysfunc- tion reversed from advanced to earlier stages (p<0.001) and exercise duration (1057±485 vs 1195±486, p=0.03) increased compared to baseline. All these pa- rameters remained unchanged in the control group. At 1-year follow-up the carvedilol group showed a significant decrease of N-BNP (p=0.02) and IL-6 (p=0.01) levels compared to the controls. At 12 months IL-1 (0.7±0.45 vs 0.58±0.34, p=0.006) and IL-6 (3.9±2.1vs 3.1±1.8, p=0.01) levels were decreased in carvedilol pts compared to baseline. The other humoral vari- ables showed no significant changes in either group. However carvedilol patients in whom diastolic function improved, N-BNP ((-0.03)--0.35 vs 0.17--0.34, p=0.04)), IL-1 ((-0.01)4-0.31 vs 0.184-0.8, p=0.04)) and IL-6 ((-0.002) 4-0.47 vs 0.264-0.34, p=0.03)) declined compared to those with unchanged (or worsened) diastolic func- tion. Baseline N-BN P correlated with baseline NYHA class (r=0.40, p=0.001 ), LVEF (r=-0.27,p=0.03) and LV diastolic filling pattern (r=0.43, p=0.001) but its alterations were only correlated with the NYHA class changes (r=0.41, p<0.001). Conclusion: Carvedilol treatment is particularly beneficial in LV function and ex- ercise capacity in NIDC patients and exerts certain anti-inflammatory effects. N- BNP, IL-1 and IL-6 level alterations seem to correlate with LV diastolic rather than systolic function, whereas serial monitoring of cytokines and/or natriuretic peptide levels provided no additional information in the evaluation of clinical stable NIDC patients.